Literature DB >> 19601721

Pharmacokinetics in special populations.

Italo Poggesi1, Margherita Strolin Benedetti, Rhys Whomsley, Sophie Le Lamer, Mathieu Molimard, Jean-Baptiste Watelet.   

Abstract

Pharmacokinetics are typically dependent on a variety of physiological variables (e.g., age, ethnicity, or pregnancy) or pathological conditions (e.g., renal and hepatic insufficiency, cardiac dysfunction, obesity, etc.). The influence of some of these conditions has not always been thoroughly assessed in the clinical studies of antiallergic drugs. However, the knowledge of the physiological grounds of the pharmacokinetics can provide some insight for predicting the potential alterations and guiding the initial prescription strategies. It is important to recognize that both pharmacokinetic and pharmacodynamic differences between populations should be considered. The available information on drugs used for the therapy of allergic diseases is reviewed in this chapter.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19601721     DOI: 10.1080/10837450902891527

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  6 in total

1.  Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs.

Authors:  Elisa Borella; Italo Poggesi; Paolo Magni
Journal:  Clin Pharmacokinet       Date:  2018-04       Impact factor: 6.447

Review 2.  Innovative clinical trial design for pediatric therapeutics.

Authors:  Matthew M Laughon; Daniel K Benjamin; Edmund V Capparelli; Gregory L Kearns; Katherine Berezny; Ian M Paul; Kelly Wade; Jeff Barrett; Phillip Brian Smith; Michael Cohen-Wolkowiez
Journal:  Expert Rev Clin Pharmacol       Date:  2011-09       Impact factor: 5.045

3.  Predicting pediatric age-matched weight and body mass index.

Authors:  Sherwin K B Sy; Eduardo Asin-Prieto; Hartmut Derendorf; Emil Samara
Journal:  AAPS J       Date:  2014-08-26       Impact factor: 4.009

4.  Anthrax edema toxin impairs clearance in mice.

Authors:  Inka Sastalla; Shixing Tang; Devorah Crown; Shihui Liu; Michael A Eckhaus; Indira K Hewlett; Stephen H Leppla; Mahtab Moayeri
Journal:  Infect Immun       Date:  2011-11-21       Impact factor: 3.441

5.  Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting.

Authors:  Camille Lenoir; Jean Terrier; Yvonne Gloor; Pauline Gosselin; Youssef Daali; Christophe Combescure; Jules Alexandre Desmeules; Caroline Flora Samer; Jean-Luc Reny; Victoria Rollason
Journal:  J Pers Med       Date:  2022-03-24

Review 6.  Obesity and COVID-19: A jigsaw puzzle with still missing pieces.

Authors:  Konstantinos Michalakis; Grigorios Panagiotou; Ioannis Ilias; Kalliopi Pazaitou-Panayiotou
Journal:  Clin Obes       Date:  2020-10-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.